Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.57 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190440 | 0.83 | CHRNB2 (0.70) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL2326712 | 0.82 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL2327327 | 0.82 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2326111 | 0.82 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2330630 | 0.82 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL6186900 | 0.80 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL6187169 | 0.80 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL2323197 | 0.79 | CHRNB2 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2330764 | 0.79 | CHRNB2 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL2327464 | 0.78 | CHRNB2 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | claimed |
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257168-A1 | DERIVATIVES OF OXABISPIDINE AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNB2 | CHRNB4 10/4885CHRNA3 7/4885CHRNB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.